Western Chongqing Southern Sichuan Precision Medicine Center Digital Platform Launches in Rongchang District
On December 24, the Western Chongqing Southern Sichuan Precision Medicine Center Digital Information Platform was...
Company
ProteLight Pharma’s Peceleganan (PL-5) Accepted for Review by China’s CDE
China’s Center for Drug Evaluation (CDE) website has indicated that a market filing by local...
Innovent Biologics Partners with Suzhou ForLong to Explore Sintilimab and FL115 Combination in Solid Tumors
China-based Innovent Biologics, Inc. (HKG: 1801) has announced a clinical study and supply agreement with...
Zhejiang Huahai Pharmaceutical’s Subsidiary Huaota Bio Secures $27.4 Million Investment
Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) has announced that its macromolecular drug-focused subsidiary, Shanghai...
Bristol-Myers Squibb’s Sotyktu Meets Primary Endpoints in POETYK PsA Studies
US pharmaceutical major Bristol-Myers Squibb (BMS; NYSE: BMY) has announced positive results from the pivotal...
Bio-Thera Solutions Enters Licensing Agreement with Tabuk Pharmaceutical for BAT2206 in Saudi Arabia
China-based Bio-Thera Solutions (SHA: 688177) has announced a licensing agreement with Tabuk Pharmaceutical Manufacturing Company,...
Achilles Therapeutics and AstraZeneca Seal $12 Billion Deal for TRACERx NSCLC Study Data
UK-based Achilles Therapeutics plc has announced a landmark deal worth USD 12 billion with AstraZeneca...
Nuvation Bio’s Taletrectinib NDA for ROS1+ NSCLC Receives FDA Priority Review
US-based Nuvation Bio Inc. (NYSE: NUVB) has announced that the New Drug Application (NDA) for...
Shanghai Henlius Biotech Initiates Patient Dosing in Global Phase III ELAINE-3 Study for Lasofoxifene
Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biopharmaceutical company based in China, has announced...
RaysightMed’s AngioQFA 100 Receives NMPA Approval for Coronary Artery Function Measurement
China-based RaysightMed Co., Ltd has announced that it has received marketing approval from the National...
uBriGene Secures RMB 200 Million in Pre-Series D Financing to Expand ATMPs CDMO Services
China-based uBriGene, a contract development and manufacturing organization (CDMO) focused on advanced therapy medicinal products...
WuXi AppTec to Divest WuXi Advanced Therapies and Oxford Genetics to Altaris LLC
China-based Contract Development and Manufacturing Organization (CDMO) WuXi AppTec Co., Ltd (SHA: 603259) has announced...
Basecare Medical and SolarCare Form Alliance to Advance AI in IVF Services
Suzhou Basecare Medical Co., Ltd (HKG: 2170), a leading China-based in vitro fertilization (IVF) specialist,...
Alphamab Oncology’s JSKN033 Gets Green Light for Phase I/II Study from China’s CDE
China-based Alphamab Oncology (HKG: 9966) has announced that it has received approval from the Center...
CSPC Pharmaceutical’s SYH2062 Receives NMPA Clearance for Hypertension Treatment
China-based CSPC Pharmaceutical Group Co., Ltd. (HKG: 1093) has announced that it has received clinical...
Keymed Biosciences’ Kangyueda Approved for CRSwNP Treatment in China
China-based Keymed Biosciences Inc., (HKG: 2162) has announced that it has received another indication approval...
Sichuan Biokin’s GNC-038 Tetra-Specific Antibody Clears for Clinical Trials in Autoimmune Diseases
Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a China-based pharmaceutical company, has announced that it...
Changchun High & New Technology Industries Receives FDA Approval for Menopausal VMS Drug Trial
China-based Changchun High & New Technology Industries (Group) Inc., (SHE: 000661) has received the green...
AstraZeneca’s Tagrisso Secures EU Approval for EGFR-Mutated Locally Advanced NSCLC
UK pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN) has announced that the European Commission (EU) has...
Ikena Oncology and Inmagene Biopharmaceuticals to Merge into ImageneBio, Listed on Nasdaq as ‘IMA’
US-based Ikena Oncology, Inc. (NASDAQ: IKNA) and Sino-US biotech Inmagene Biopharmaceuticals have announced their merger...